Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Short-term Investments: 2009-2025

Historic Short-term Investments for UNITED THERAPEUTICS (UTHR) over the last 17 years, with Sep 2025 value amounting to $1.4 billion.

  • UNITED THERAPEUTICS's Short-term Investments fell 19.47% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year decrease of 19.47%. This contributed to the annual value of $1.6 billion for FY2024, which is 12.12% down from last year.
  • Latest data reveals that UNITED THERAPEUTICS reported Short-term Investments of $1.4 billion as of Q3 2025, which was down 1.93% from $1.5 billion recorded in Q2 2025.
  • UNITED THERAPEUTICS's Short-term Investments' 5-year high stood at $1.9 billion during Q4 2022, with a 5-year trough of $899.0 million in Q1 2021.
  • Its 3-year average for Short-term Investments is $1.6 billion, with a median of $1.6 billion in 2023.
  • In the last 5 years, UNITED THERAPEUTICS's Short-term Investments surged by 81.24% in 2022 and then dropped by 19.47% in 2025.
  • MRQ analysis of 5 years shows UNITED THERAPEUTICS's Short-term Investments stood at $1.0 billion in 2021, then soared by 81.24% to $1.9 billion in 2022, then dropped by 4.85% to $1.8 billion in 2023, then dropped by 12.12% to $1.6 billion in 2024, then fell by 9.06% to $1.4 billion in 2025.
  • Its last three reported values are $1.4 billion in Q3 2025, $1.5 billion for Q2 2025, and $1.4 billion during Q1 2025.